Lv1
60 积分 2022-07-31 加入
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
4天前
已完结
肿瘤免疫治疗相关肝损伤的研究进展
2个月前
已完结
肿瘤免疫治疗相关肝损伤的研究进展
3个月前
已完结
Checkpoint inhibitor hepatotoxicity: pathogenesis and management
3个月前
已完结
Immune checkpoints in the tumor microenvironment
3个月前
已完结
The multiple roles of LDH in cancer
3个月前
已完结
Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
3个月前
已完结
Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial
3个月前
已完结
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
3个月前
已完结
600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ERBB2-Negative Advanced Breast Cancer
6个月前
已完结
皖公网安备34019202002308
